5MJC BCU 8: AVADO — Final Overall Survival Results of First-Line Docetaxel in Combination with Escalating Doses of Bevacizumab for HER2-Negative Metastatic Breast Cancer
AVADO — Final Overall Survival Results of First-Line Docetaxel in Combination with Escalating Doses of Bevacizumab for HER2-Negative Metastatic Breast Cancer
5MJC BCU 7: RIBBON 2 — A Phase III Trial of Second-Line Bevacizumab in Combination with Chemotherapy for HER2-Negative Metastatic Breast Cancer
RIBBON 2 — A Phase III Trial of Second-Line Bevacizumab in Combination with Chemotherapy for HER2-Negative Metastatic Breast Cancer
5MJC BCU 5: Loading Dose Schedule of Fulvestrant Combined with Anastrozole for the Treatment of Patients with Breast Cancer at First Relapse
Loading Dose Schedule of Fulvestrant Combined with Anastrozole for the Treatment of Patients with Breast Cancer at First Relapse
5MJC BCU 4: High-Dose Fulvestrant for the Treatment of Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
High-Dose Fulvestrant for the Treatment of Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
5MJC BCU 6: Tumor Biomarker Changes After Presurgical Treatment of Patients with Breast Cancer with High-Dose Fulvestrant and Anastrozole
Tumor Biomarker Changes After Presurgical Treatment of Patients with Breast Cancer with High-Dose Fulvestrant and Anastrozole
5MJC BCU 3: Phase II Study of Trastuzumab-DM1 (T-DM1) for Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Phase II Study of Trastuzumab-DM1 (T-DM1) for Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
5MJC BCU 2: NCCTG-N9831: Adjuvant Chemotherapy Alone or with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in HER2-Positive Breast Cancer
NCCTG-N9831: Adjuvant Chemotherapy Alone or with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in HER2-Positive Breast Cancer
5MJC BCU 1: Efficacy of Trastuzumab-Based Regimens in Patients with HER2-Amplified Early-Stage Breast Cancer
Efficacy of Trastuzumab-Based Regimens in Patients with HER2-Amplified Early-Stage Breast Cancer
Year in Review - Lung Cancer Edition 2009
Year in Review - Lung Cancer Edition 2009 |
|---|
|
A CME monograph and speaker’s slide kit summarizing the year’s most important meeting presentations and journal articles.
|
5MJC MDS/AML 17: Links
Studies on the Efficacy and Safety of Deferasirox for Iron Chelation in Patients with MDS: EPIC and US03
5MJC MDS/AML 15: Safety and Efficacy of Combination Therapies with Azacitidine in Elderly Patients with AML or MDS
Safety and Efficacy of Combination Therapies with Azacitidine in Elderly Patients with AML or MDS
5MJC MDS/AML 16: Phase II Study of Maintenance Treatment with 5-Azacitidine for Patients with MDS or Post-MDS AML
Phase II Study of Maintenance Treatment with 5-Azacitidine for Patients with MDS or Post-MDS AML
5MJC MDS/AML 19: Patterns of Care Survey for Myelodysplastic Syndromes (MDS)
Patterns of Care Survey for Myelodysplastic Syndromes (MDS)
5MJC MDS/AML 17: Studies on the Efficacy and Safety of Deferasirox for Iron Chelation in Patients with MDS: EPIC and US03
Studies on the Efficacy and Safety of Deferasirox for Iron Chelation in Patients with MDS: EPIC and US03
5MJC MDS/AML 18: Lenalidomide Activity in AML with Trisomy 13
Lenalidomide Activity in AML with Trisomy 13